Treatment of SARS Caused by COVID-19 With Ruxolitinib
NCT04334044
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
77
Enrollment
OTHER
Sponsor class
Conditions
COVID-19
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
DRUG:
Ruxolitinib Oral Tablet
Sponsor
Grupo Cooperativo de Hemopatías Malignas